Selective Inhibition of Tyrosine Kinase 2 With Deucravacitinib (BMS-986165) Compared With Janus Kinase 1−3 Inhibitors

Main Article Content

Anjaneya Chimalakonda
James Burke
Lihong Cheng
Ian Catlett
Aditya Patel
Jun Shen
Ihab Girgis
Subhashis Banerjee
John Throup

Keywords

Pharmacology, Tyrosine Kinase 2 Inhibitor, Deucravacitinib, Janus Kinase Inhibitor, JAK, TYK2

Abstract

Abstract not available.

References

1. Burke JR et al. Sci Transl Med. 2019;11:1-16.

2. Papp K et al. N Engl J Med. 2018;379:1313-1321.

3. Girgis IG et al. Presented at: Triennial Meeting of the Skin Inflammation and Psoriasis International Network; April 25-27, 2019; Paris, France.

4. Klünder B et al. Clin Pharmacokinet. 2019;58:1045-1058.

5. Xie R et al. Int J Clin Pharmacol Ther. 2019;57:464-473.

6. Zhang X et al. CPT Pharmacometrics Syst Pharmacol. 2017;6:804-813.

7. Dowty ME et al. Pharmacol Res Perspect. 2019;7:e00537.

8. McInnes IB et al. Arthritis Res Ther. 2019;21:183.

9. Xeljanz [package insert]. New York, NY: Pfizer Inc.; 2019.

10. Winthrop KL. Nat Rev Rheumatol. 2017;13:234-243.

11. Gadina M et al. Rheumatology (Oxford). 2019;58:i4-i16.